Bedrijfsupdate28 sep 2026ENGENFIT Reports First-Half 2026 Financial Results and Provides Corporate UpdateGENFIT S.A.Company newsroom
Bedrijfsupdate14 sep 2026ENGENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLFGENFIT S.A.Company newsroom
Bedrijfsupdate11 sep 2026ENGENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext ParisGENFIT S.A.Company newsroom
Bedrijfsupdate10 sep 2026ENGENFIT to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGENFIT S.A.Company newsroom
Bedrijfsupdate9 sep 2026ENGENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics TechnologyGENFIT S.A.Company newsroom
Bedrijfsupdate3 sep 2026ENGENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026GENFIT S.A.Company newsroom
Bedrijfsupdate8 jul 2026ENGenfit: Half-Year Report of Liquidity Contract with Crédit Industriel et CommercialGENFIT S.A.Company newsroom
Bedrijfsupdate2 jul 2026ENGENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASHGENFIT S.A.Company newsroom
Bedrijfsupdate23 jun 2026ENGENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with CholangiocarcinomaGENFIT S.A.Company newsroom
Bedrijfsupdate15 jun 2026ENGENFIT: June 15, 2026 Combined Shareholders Meeting ResultsGENFIT S.A.Company newsroom
Bedrijfsupdate8 jun 2026ENGENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASHGENFIT S.A.Company newsroom
Bedrijfsupdate25 mei 2026ENGENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026GENFIT S.A.Company newsroom
Bedrijfsupdate21 mei 2026ENGENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate UpdateGENFIT S.A.Company newsroom
Bedrijfsupdate11 mei 2026ENGENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory DocumentsGENFIT S.A.Company newsroom
Bedrijfsupdate20 apr 2026ENGENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)GENFIT S.A.Company newsroom
Bedrijfsupdate7 apr 2026ENGENFIT Announces Publication of the 2025 Universal Registration DocumentGENFIT S.A.Company newsroom
Bedrijfsupdate2 apr 2026ENGENFIT Reports Full-Year 2025 Financial Results and Provides Corporate UpdateGENFIT S.A.Company newsroom
Bedrijfsupdate9 mrt 2026ENGENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLFGENFIT S.A.Company newsroom
Bedrijfsupdate26 feb 2026ENGENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate UpdateGENFIT S.A.Company newsroom
Bedrijfsupdate12 feb 2026ENGENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net salesGENFIT S.A.Company newsroom
